Generic apixaban has been approved by the FDA for years. It still isn't sold in American pharmacies — and under current patent agreements, it won't be until at least April 2028.
Key points
- Multiple manufacturers hold FDA approval to make generic apixaban, but patent settlements bar them from selling it in the U.S. before April 1, 2028.
- A separate group of manufacturers remains in litigation and could be blocked until the formulation patent expires in 2031.
- Medicare's negotiated price of $231 per 30-day supply took effect January 1, 2026 — a 56% cut, but it applies only to Part D enrollees and it is still brand-name pricing.
- Generic apixaban is approved and sold in other countries, including Canada, at generic-level prices.
Approved to Make, Not Approved to Sell
The confusion around generic Eliquis comes from a distinction that isn't obvious to most patients: FDA approval and market availability are two separate things.
Several generic manufacturers have already satisfied the FDA that their apixaban products are bioequivalent to Eliquis — same active ingredient, same strength, same clinical effect. What they don't have is legal clearance to sell those products in the United States.
Eliquis is co-marketed by Bristol Myers Squibb and Pfizer, who hold a portfolio of patents covering the drug. Rather than fight every generic challenger to a verdict, the brand manufacturers settled with most of them. The terms of those settlements set an agreed date after which the generics may launch. That date is April 1, 2028.
When a U.S. Generic Could Actually Arrive
Three timelines are worth understanding, because they don't all point to the same year:
- April 1, 2028 — the settled launch date for the majority of generic manufacturers. This is the earliest realistic date for generic apixaban in U.S. pharmacies.
- 2031 — a smaller group of manufacturers litigated rather than settled, lost, and cannot launch until the formulation patent expires. If the 2028 date were disrupted, this becomes the operative horizon.
- Earlier, in theory — the patents remain open to future challenge, and both companies have acknowledged that certain outcomes could permit an earlier generic launch. Nothing currently suggests that is imminent.
For a patient managing atrial fibrillation or clot prevention today, the practical answer is that a domestically sold generic is years away, not months.
What Medicare's Negotiated Price Did — and Didn't — Change
Eliquis was among the first ten drugs selected for price negotiation under the Inflation Reduction Act. The negotiated maximum fair price took effect January 1, 2026: $231 for a 30-day supply, down from a list price of roughly $521.
That is a meaningful reduction, and for Medicare Part D enrollees it is real money — particularly alongside the $2,100 annual out-of-pocket cap that also took effect in 2026. But two limits are worth being clear about. The negotiated price applies only within Medicare, so patients with commercial insurance or no coverage don't see it. And $231 a month is a discounted brand-name price, not a generic price. Generic competition typically drives costs down far further than negotiation does.
What Apixaban Costs Today, by Source
The chart below compares approximate monthly costs across the options currently in front of U.S. patients, plus the U.S. generic that isn't available yet.
| Source | Cost (30-day supply) | Available | Notes |
|---|---|---|---|
| Brand-name Eliquis U.S. retail / cash | ~$521 | Available now | Full list price before insurance, rebates, or manufacturer discounts. |
| Brand-name Eliquis Medicare negotiated price | $231 | Jan 1, 2026 | Medicare Part D enrollees only. Actual copay depends on plan tier and deductible. |
| Generic apixaban U.S. pharmacies | ? | 2028 – 2031 | FDA-approved but blocked from sale by patent settlements. No pricing exists until launch. |
| Generic apixaban Canada, by mail order | $50–$100 | Available now | Health Canada-approved and dispensed against a valid prescription by licensed Canadian pharmacies that ship to U.S. patients. |
Generic Apixaban Exists — Just Not in the U.S.
The patent situation that blocks generic apixaban is specific to the United States. In Canada, generic apixaban has been approved by Health Canada and is dispensed routinely, manufactured to the same bioequivalence standards required of any generic that replaces a brand-name drug.
Because it competes as a generic in that market, it carries generic pricing — typically in the range of $50 to $100 for a 30-day supply, well below both the U.S. list price and the Medicare-negotiated brand price.
Many Americans order maintenance medications from licensed Canadian pharmacies for personal use, particularly where a U.S. brand-name drug has no domestic generic competition. Rules around personal importation are a matter for each patient to research and decide on; nothing in this article is legal advice. Anyone considering it should speak with their own physician or pharmacist first, and should confirm that any pharmacy they use is licensed and requires a valid prescription.
What This Means for Patients
Anticoagulants like apixaban are not medications to stop, switch, or ration over cost, and cost pressure on a maintenance drug is worth raising with a prescriber rather than absorbing quietly. Depending on circumstances, options may include the manufacturer's patient assistance program, a different anticoagulant with an available generic such as rivaroxaban or warfarin, Medicare plan comparison during open enrollment, or sourcing a Health Canada-approved generic from a licensed pharmacy.
What isn't an option, for the next several years, is buying generic apixaban at an American pharmacy counter.
Frequently Asked Questions
Is generic apixaban the same as Eliquis?
A generic must contain the same active ingredient at the same strength and demonstrate bioequivalence to the brand-name product. Generic apixaban approved in Canada is held to that standard by Health Canada, as FDA-approved generics are in the United States.
Why is Eliquis so expensive without a generic?
Brand-name drugs face no price competition until a generic enters the market. Medicare's negotiated price reduces what the program pays, but it doesn't introduce competition, and it doesn't reach patients outside Medicare.
Will the April 2028 date move?
It could, in either direction. The date comes from private settlement agreements rather than statute, and the underlying patents remain open to challenge. Nothing currently indicates an earlier launch.
Can I get generic apixaban from another country?
Generic apixaban is approved and sold in a number of markets outside the United States, including Canada. Personal importation rules are something each patient should research independently; a prescription from a licensed provider is required either way. Pharmacies that ship to U.S. patients should be licensed and should require that prescription before dispensing.
Sources
- Pfizer Inc., Form 10-K annual report — Eliquis patent litigation and settlement terms.
- Centers for Medicare & Medicaid Services — Medicare Drug Price Negotiation Program, negotiated maximum fair prices effective January 1, 2026.
- U.S. Food and Drug Administration — Orange Book approvals for apixaban.
- Health Canada — Drug Product Database, apixaban.
This information is intended for general educational purposes for patients and healthcare professionals. It does not replace professional medical advice, diagnosis, or treatment. Always consult a licensed physician or pharmacist before starting, stopping, or changing any medication. This medication requires a valid prescription issued by a licensed healthcare provider. Pricing shown is approximate and subject to change. Nothing in this article constitutes legal advice regarding personal importation of medication.
Leave a Reply